Profile: Evocutis PLC (EVO.L)

EVO.L on London Stock Exchange

0.43GBp
24 Oct 2014
Price Change (% chg)

0.00p (+0.00%)
Prev Close
0.43p
Open
0.43p
Day's High
--
Day's Low
--
Volume
775,699
Avg. Vol
6,911,123
52-wk High
1.30p
52-wk Low
0.16p

Search Stocks
Evocutis plc is engaged in the provision of skin microbiology and clinical dermatology services to companies in pharmaceutical and consumer healthcare markets, using the Company’s living skin technology, LabSkin. The three main areas of its activity include Specialist skin microbiology research and products, such as SYN1113; Skin microbiology laboratory services to support Clinical Research Organisations, and development of LabSkin and its use for contract research with sponsor companies and its direct sale as a research product. The Company offer combination of contract research services to dermatology researchers and product developers. Its contract research and consultancy services include Skin Microbiology; Microbiology to support clinical studies and Research using its Living Skin Equivalent Model (LabSkin). In February 2014, Venn Life Sciences Holdings completed the acquisition of the intellectual property rights in Labskin, SYN1113 and related equipment of Evocutis plc.

Company Address

Evocutis PLC

Suite 3B, 38 Jermyn Street
LONDON   ENG   SW1Y 6DN
P: +44845.2008341

Search Stocks